(Reuters) - Israel's Teva Pharmaceutical Inc said on Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis showed that the drug was unlikely to meet the study's main goal.
Original Article: Teva to discontinue study for chronic headache treatment